serw-MX  [xml]  
 


    
 DeCS Categories

D26 Pharmaceutical Preparations .
D26.255 Dosage Forms .
E02 Therapeutics .
E02.319 Drug Therapy .
E02.319.267 Drug Administration Routes .
E02.319.890 Self Administration .
E02.900 Self Care .
E02.900.890 Self Administration .
E05 Investigative Techniques .
E05.318 Epidemiologic Methods .
E05.318.760 Epidemiologic Study Characteristics .
E05.318.760.250 Clinical Studies as Topic .
E05.318.760.250.500 Clinical Trials as Topic .
E05.318.760.250.500.200 Clinical Trials, Phase I as Topic .
E05.337 Evaluation Studies as Topic .
E05.337.425 Drug Evaluation .
E05.916 Technology, Pharmaceutical .
E05.916.250 Dosage Forms .
N05 Health Care Quality, Access, and Evaluation .
N05.715 Quality of Health Care .
N05.715.360 Health Care Evaluation Mechanisms .
N05.715.360.775 Epidemiologic Study Characteristics .
N05.715.360.775.088 Clinical Studies as Topic .
N05.715.360.775.088.500 Clinical Trials as Topic .
N05.715.360.775.088.500.200 Clinical Trials, Phase I as Topic .
N06 Environment and Public Health .
N06.850 Public Health .
N06.850.520 Epidemiologic Methods .
N06.850.520.450 Epidemiologic Study Characteristics .
N06.850.520.450.250 Clinical Studies as Topic .
N06.850.520.450.250.250 Clinical Trials as Topic .
N06.850.520.450.250.250.200 Clinical Trials, Phase I as Topic .
VS2 Health Surveillance of Products .
VS2.002 Drug and Narcotic Control .
VS2.002.002 Chemical Industry .
VS2.002.002.001 Drug Industry .
VS2.002.002.001.001 Technology, Pharmaceutical .
VS2.002.002.001.001.010 Dosage Forms .
VS2.002.003 Drug Evaluation .
VS2.002.003.001 Drug Approval .
VS2.002.003.001.003 Clinical Trials as Topic .
VS2.002.003.001.003.001 Clinical Trials, Phase I as Topic .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Drug Evaluation .
Drug Evaluation Studies .
Drug Evaluation Study .
Drug Evaluations .
Evaluation Study, Drug .
Evaluation, Drug .
Evaluations, Drug .
Studies, Drug Evaluation .
Study, Drug Evaluation .
Evaluation Studies, Drug .
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. .
1.00
 
Drug Administration Routes .
Administration Routes, Drug .
Administration Route, Drug .
Drug Administration Route .
Route, Drug Administration .
Routes, Drug Administration .
The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue. .
0.38
 
Self Administration .
Administration, Self .
Administrations, Self .
Self Administrations .
Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal. .
0.37
 
Clinical Trials, Phase I as Topic .
Clinical Trials, Phase 1 .
Drug Evaluation, FDA Phase 1 .
Drug Evaluation, FDA Phase I as Topic .
Evaluation Studies, FDA Phase 1 .
Human Microdosing Trials .
Microdosing Trials, Human .
Phase 1 Clinical Trials .
Human Microdosing Trial .
Microdosing Trial, Human .
Trial, Human Microdosing .
Trials, Human Microdosing .
Clinical Trials, Phase I .
Drug Evaluation, FDA Phase I .
Evaluation Studies, FDA Phase I .
Phase I Clinical Trials .
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries. .
0.36
 
Dosage Forms .
Dosage Form .
Form, Dosage .
Forms, Dosage .
Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. .
0.35